LETTER TO THE EDITOR

# Subcutaneous azacitidine maintenance in transplant-ineligible patients with acute myeloid leukemia: a single-center retrospective study

Natacha Johnson,[1] Marie Templé,[2] Chloe Friedrich,[2,3] Lise Willems,[1] Rudy Birsen,[1] Marguerite Vignon,[1] Paul Deschamps,[1] Patricia Franchi,[1] Johanna Mondesir,[1] Benedicte Deau-Fischer,[1] Elsa Miekoutima,[1] Ismaël Boussaid,[2] Nicolas Chapuis,[2,3] Olivier Kosmider,[2,3] Didier Bouscary,[1,3] Jerome Tamburini[1,3,4,5] and Justine Decroocq[1]

[1]Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France; [2]Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Cochin Hospital, Paris, France; [3]Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France; [4]Translational Research Center in Onco-hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland and [5]Swiss Cancer Center Leman, Geneva, Switzerland

Correspondence:
J. DECROOCQ - justine.decroocq@aphp.fr

https://doi.org/10.3324/haematol.2022.282009

## Supplemental data

**Table S1. Record of toxicities during AZA maintenance**.

| | **N = 39** |
|---|---|
| AZA maintenance cycles | |
| Median (range) | 6 (1-38) |
| Mean (standard deviation) | 10.7 (10.5) |
| AZA schedule modification, n (%) | |
| Yes | 14 (36) |
| No | 22 (56) |
| Missing data | 3 (8) |
| Type of modification, n (%) | |
| 5 days AZA every 28 days | 7 (18) |
| 7 days AZA every 6 weeks | 4 (10) |
| 5 days AZA every 6 weeks | 3 (8) |
| Cause of dose reduction, n (%) | |
| Cytopenia | 9 (23) |
| Infection | 3 (8) |
| Nausea | 1 (2.5) |
| Systematic reduction | 1 (2.5) |
| Cause of AZA discontinuation, n (%) | |
| Persistent CR | 7 (18) |
| HSCT | 2 (5) |
| Relapse/progression | 14 (36) |
| Other cancer | 1 (2,5) |
| Death | 1 (2,5) |
| Cytopenia | 3 (8) |
| Infection | 3 (8) |
| Nausea | 1 (2,5) |
| Unknown | 3 (8) |
| Patients receiving AZA at end of follow up, n (%) | 4 (10) |

**Figure S1. Genomic landscape at diagnostic of patients treated with AZA maintenance.**




**Legend**

DNA methylation
Chromatin-cohesin
RTK-RAS signaling
Splicing
Transcription
Other

| | | | | |
|---|---|---|---|---|
| ELN 2017 | Adv | Int | Fav | |
| Cytogenetics | Adv | Int | Fav | Unknown |
| MRD | Positive | Negative | Unknown | |

**Figure S2. Hypothesis on clonal evolution during AZA maintenance.** The first time point (referred to as month 0) corresponds to diagnosis. Next, the following point corresponds to remission and variant allele frequency is by convention represented at 0% at month 1 as in most situation (except patients 6 and 22) NGS was not performed on remission samples. In one case (Patient 22), NGS was performed during a first remission, then at relapse, then during a second remission and finally at the time of a second relapse at month 63. Clonal evolution illustrations were performed using the "fishplot" package for R (version 0.5.1).